CryoLife Target of Unusually Large Options Trading (NYSE:CRY)


Share on StockTwits

CryoLife, Inc. (NYSE:CRY) saw some unusual options trading activity on Monday. Traders acquired 1,565 put options on the stock. This represents an increase of approximately 3,030% compared to the typical volume of 50 put options.

CRY has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of CryoLife from a “sell” rating to a “hold” rating in a research note on Wednesday, April 14th. Needham & Company LLC increased their price target on shares of CryoLife from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Friday.

In other CryoLife news, SVP Jean F. Holloway sold 1,693 shares of the company’s stock in a transaction dated Wednesday, March 10th. The shares were sold at an average price of $25.28, for a total transaction of $42,799.04. Also, VP Dennis B. Maier sold 7,197 shares of the company’s stock in a transaction dated Wednesday, February 17th. The shares were sold at an average price of $24.73, for a total transaction of $177,981.81. Following the sale, the vice president now directly owns 23,211 shares in the company, valued at $574,008.03. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its stake in CryoLife by 9.7% in the fourth quarter. BlackRock Inc. now owns 6,816,729 shares of the medical equipment provider’s stock worth $160,944,000 after acquiring an additional 601,274 shares during the period. Morgan Stanley lifted its stake in CryoLife by 9.6% in the fourth quarter. Morgan Stanley now owns 1,552,583 shares of the medical equipment provider’s stock worth $36,656,000 after acquiring an additional 136,492 shares during the period. New York State Common Retirement Fund lifted its stake in CryoLife by 76.6% in the fourth quarter. New York State Common Retirement Fund now owns 292,743 shares of the medical equipment provider’s stock worth $6,912,000 after acquiring an additional 126,960 shares during the period. Victory Capital Management Inc. purchased a new stake in CryoLife in the first quarter worth $2,599,000. Finally, William Blair Investment Management LLC lifted its stake in CryoLife by 10.8% in the fourth quarter. William Blair Investment Management LLC now owns 878,473 shares of the medical equipment provider’s stock worth $20,741,000 after acquiring an additional 85,843 shares during the period. Hedge funds and other institutional investors own 80.92% of the company’s stock.

Shares of CryoLife stock traded up $0.38 on Tuesday, hitting $28.70. The stock had a trading volume of 4,971 shares, compared to its average volume of 197,225. The company has a quick ratio of 3.06, a current ratio of 4.35 and a debt-to-equity ratio of 0.89. CryoLife has a one year low of $16.13 and a one year high of $30.00. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -74.23, a PEG ratio of 161.60 and a beta of 1.47. The stock’s 50-day simple moving average is $23.26 and its two-hundred day simple moving average is $22.77.

CryoLife (NYSE:CRY) last issued its earnings results on Thursday, April 29th. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. CryoLife had a negative net margin of 5.45% and a positive return on equity of 1.86%. As a group, equities analysts predict that CryoLife will post 0.01 EPS for the current fiscal year.

About CryoLife

CryoLife, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system.

See Also: Book Value Per Share in Stock Trading

Receive News & Ratings for CryoLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife and related companies with MarketBeat.com's FREE daily email newsletter.